A novel series of imidazo[1,2-α]pyridines was designed, synthesized, and tested for their ability to inhibit acylCoA:cholesterol acyltransferase. Preliminary lead optimization efforts resulted in the identification of ACAT inhibitors represented by analogues 5b, 5c, 6a, 6c, 7b, and 7c. The ACAT inhibitory activity of these compounds was further established by potent inhibition of cholesteryl ester formation in HepG2 cells by a representative analogue 7b.
Introduction 1
Acyl-CoA:cholesterol acyltransferase (ACAT) is a microsomal enzyme that catalyzes biotransformation of free cholesterol to cholesterol esters.
1 Accumulation of cholesterol ester brings about the formation of foam cells from macrophages in the arterial walls, which is a hallmark of atherosclerosis lesions. 2, 3 Inhibition of ACAT enzyme activity would therefore reduce plasma cholesterol levels by blocking intestinal cholesterol absorption. 4 Thus, ACAT represents an attractive target for therapeutics designed to have potent hypocholesterolemic and antiarteriosclerotic properties. As a result, considerable efforts have been devoted in recent years to the discovery and development of structurally diversed compounds showing potent ACAT inhibitory activity. 5, 6 Imidazo[1, 2-a] pyridines, a novel class of pharmaceutical compounds exhibit a broad range of biological activities. 7 Besides, imidazo[1, 2-a] pyridine scaffold is found in a number of marketed drug formulations, such as zolimidine (an antiulcer drug), zolpidem (ahypnotic drug), and alpidem (a nonsedative anxiolytic) (Figure 1 ). 8 As a result, numerous reports have described the structural modifications of this scaffold with the aim of developing novel therapeutic agents. In view of these findings and with the objective to develop a potent ACAT inhibitor, we performed the synthesis of a new series of imidazo [1,2-a] pyridines and evaluation of their ACAT inhibitory activity. Herein, we describe our preliminary lead optimization efforts culminating in the identification of a novel series of imidazo [1,2-a] pyridines as potent ACAT inhibitors.
Various 2 and 6-substituted imidazo[1,2-a]pyridines, 5a-k, 6a-i and 7a-c were synthesized as outlined in Schemes 1-3. The most common approach for the synthesis of imidazo-[1, 2-a] pyridines involves the condensation of α-haloketones with 2-aminopyridines. 9 Accordingly, the synthesis of initial a These authors equally contributed to this work.
series of imidazo[1,2-a]pyridine analogues 5a-k were obtained starting from 2-amino-5-bromo pyridine and 2-bromo-1-(3-nitrophenyl)ethanone (Scheme 1). Thus, coupling of 1 with 2 under reflux conditions in a mixture of acetone and ethanol gave 3 in good yield. Subsequent reduction of the nitro group with tin chloride provided the corresponding amino derivative 4 in 82% yield. For the purpose of preliminary structure activity relationship studies, it was chosen to derivatize the amino group whilst keeping the other end group halogen intact. Consequently, coupling of 4 with suitable benzoic acids using appropriate coupling agents such as PyBOP, HATU or EDC in the presence of Hunig's base furnished the corresponding amide analogues 5a-i in moderate to excellent yields. Further reaction of 4 with appropriate sulfonyl chlorides in presence of Hunig's base afforded the remaining amide derivatives 5j and 5k.
After elaboration of the amino group, we set out to explore the derivatization of halogen group. Thus, compound 5c, moderate ACAT inhibitor amongst 5a-k series was subjected to Suzuki cross coupling with appropriate boronic acids to yield the desired cross-coupled products 6a-i (Scheme 2) in modest to high yields.
As shown in Scheme 3, further reaction of phenol 6i with trichloroacetyl isocyanate and ethyl chloroacetate furnished corresponding amide 7a and ester 7b derivatives, respectively. Subsequent alkaline hydrolysis of 7b afforded the respective acid analogue 7c in good yield (Scheme 3) . a Reagents and conditions: (i) acetone: absolute ethanol (1:1), reflux, 12 h; (ii) SnCl2, MeOH, reflux, 12 h; (iii) RCO2H, PyBOP, DIPEA, DMF, rt, 12 h for 5a, 5h and 5i; HATU, DIPEA, DMF, rt, 12 h for 5b and 5e; HBTU, DIPEA, DMF, rt, 12 h for 5c; EDC, HOAt, DIPEA, DMF, rt, 12 h for 5d; EDC, HOBt, DIPEA, DMF, rt, 12 h for 5f and 5g; (iv) RSO2Cl, TEA, CH2Cl2, 0 o C, 2 h for 5j and 5k. a Reagents and conditions: (i) RB(OH)2, Pd(PPh3)4, NaH-CO3, DME, H2O, reflux, 12 h. The newly synthesized compounds were evaluated in vitro for their potential to inhibit human macrophage ACAT activity using a cell-based reporter assay in human HepG2 cell lines and the results are tabulated as IC50 values in Table 1 and 3 . All the assays were performed under standard assay conditions by employing the previously described assay protocol. 10 Pipercide, a known ACAT inhibitor, was used as a reference standard for comparison, which displayed potent ACAT inhibitory activity with an IC50 of 3.7 µM. 10 In order to establish the preliminary structure activity relationship studies, compound 4 which is amenable for easy derivatization at both the ends was chosen as a starting template for the generation of a new series of ACAT inhibitors. At first, we explored the derivatization of amino group of 4 whilst maintaining halogen substituent on 6-poisition of pyridine ring. Thus, compounds 5a-k were obtained by the reaction of 4 with appropriate benzoic acids/sulfonyl chlorides and the in vitro ACAT inhibitory potencies of these compounds are presented in Table 1 . Of these, naphthamide analogues 5b and 5c exhibited signi- ficant ACAT inhibitory activity of 48% and 56% at the concentration of 25 µg/mL, respectively. As shown in Table 2 , compound 5c inhibited the ACAT activity in a dose dependent manner. On the other hand, all of the other derivatives displayed weak inhibitory activity. In view of the significant potency of compound 5c, we prepared more analogues of 5c by introducing various aryl groups at 6-position of pyridine ring while retaining the 2-naphthamide moiety on 3-phenyl ring. Thus, compounds 6a-i and 7a-c were obtained as described in Schemes 2 and 3, respectively, and in vitro inhibitory potencies of these compounds are tabulated in Table 3 . Interestingly, this modification provided potent inhibitors represented by analogues 6a and 6c. In general, introduction of nonpolar aromatic ring at 6-position of pyridine ring such as 2,4-difluorobenzene, and 2-naphthalene showed inhibitory activity of ACAT. However, polar residues such as phenol, p-methylsulfonylbenzene, mcyanobenzene did not exhibited the inhibitory activity. Likewise, absence of the inhibitory activity of phenolic analogue may be reasoned due to polar hydroxyl group. Therefore, the inhibitory activity was induced by masking of the hydroxyl group of 6i as shown in the case of 7b, which displayed significant ACAT inhibitory activity with IC50 value of 8.7 µM. Compound 7b inhibited ACAT activity in a dose dependent manner and 86% inhibition was observed at 100 µM. The corresponding acid 7c showed two fold decreased inhibitory activity in comparison with 7b and carbamate 7a lost the inhibitory activity.
To confirm the ACAT inhibitory potency of imidazo[1,2-a]pyridines, 7b was chosen for further evaluation. Accordingly, this analogue was evaluated by Western blot analysis for its potential to inhibit ACAT activity in HepG2 cells. As shown in Figure 2 , compound 7b exhibited complete inhibition at 30 µM with an IC50 value of 2.02 µM in a dose dependent manner confirming the ACAT inhibitory property of this compound.
Several studies have demonstrated that ACAT inhibitors reduce the plasma cholesterol levels by blocking cholesterol absorption in animal models. Among the current series, compound 7b was therefore investigated for its inhibitory potency of cholesterol ester formation in HepG2 cells. As shown in Table 5 , compound 7b significantly reduced the cholesterol ester formation in HepG2 cells in a dose-dependent manner. This data further proves the hypothesis reported in the earlier reports that ACAT inhibitors reduce the plasma cholesterol levels. However, more detailed studies are required to establish the mechanism of action of these inhibitors.
In conclusion, a novel series of various 2 and 6-substituted imidazo[1,2-a]pyridines were prepared and evaluated for their ability to inhibit ACAT activity. Preliminary lead optimization efforts resulted in the identification of potent ACAT inhibitors represented by analogues 6a, 6c, 7b and 7c. The ACAT inhibitory activity of these compounds was further established by potent inhibition of ACAT activity in HepG2 cell line by a representative analogue 7b which exhibited ACAT inhibition in a dose dependent manner. Based on these results, this analogue was further investigated for its ability to reduce cholesterol ester formation in HepG2 cells. Interestingly, compound 7b significantly reduced the cholesterol ester formation in a dose-dependent manner and further investigations are necessary to know the mechanism of action of these inhibitors.
Experimental Section
All of the commercial chemicals and solvents are of reagent grade and were used without further purification. All reactions were carried out under an atmosphere of dried argon, in flamedried glassware. Proton nuclear magnetic resonance ( 1 H NMR) spectra were determined on a Varian (300 MHz) spectrometer. Chemical shifts are provided in parts per million (ppm) downfield from tetramethylsilane (internal standard) with coupling constants in hertz (Hz). Multiplicity is indicated by the following abbreviations: singlet (s), doublet (d), doublet of doublet (dd), triplet (t), pseudo triplet (ps-t), quartet (q), multiplet (m), broad (br). Mass spectra were recorded on a Finnigan ESI mass spectrometer and HRMS (EI-MS) was obtained on a JMS-700 (Jeol, Japan). Products from all reactions were purified to a minimum purity of 96% as determined by HPLC, either by flash column chromatography using silica gel 60 (230-400 mesh Kieselgel 60) or by preparative thin layer chromatography using glass-backed silica gel plates (1 mm thickness) unless otherwise indicated. Additionally, thinlayer chromatography on 0.25 mm silica plates (E. Merck, silica gel 60 F254) was used to monitor reactions. The chromatograms were visualized using ultraviolet illumination, exposure to iodine vapors, dipping in PMA or Hanessian's solution. The purity of the products was checked by reversed phase high-pressure liquid chromatography (RP-HPLC), which was performed either on Dionex Corp. HPLC system or on Waters Corp. HPLC system equipped with a UV detector set at 254 nm. The mobile phases used were A: H2O containing 0.05% TFA, and B: CH3CN. The HPLC employed an YMC Hydrosphere C18 (HS-302) column (5 µ particle size, 12 nM pore size), 4.6 mm dia. × 150 mm with a flow rate of 1.0 mL/min. Compound purity was assessed using one of the following methods, Method A: gradient 20% B to 100% B in 20 min (Waters Corp. HPLC system); Method B: gradient 20% B to 100% B in 30 min (Dionex Corp. HPLC system).
6-Bromo-2-(3-nitro-phenyl)-imidazo[1,2-a]pyridine (3):
A solution of 5-bromo-pyridin-2-ylamine (1) (779 mg, 4.50 mmol) and 2-bromo-1-(3-nitro-phenyl)-ethanone (2) (732 mg, 3.00 mmol) in acetone and ethanol (20 mL, 1:1) was refluxed overnight. The reaction mixture was concentrated at reduce pressure and then partitioned between ethyl acetate and brine. The organic phase was dried (MgSO4), and concentrated. Purification by silica gel column chromatography (CH2Cl2: MeOH = 30:1) gave 6-bromo-2- (3) (335 mg, 1.05 mmol) and SnCl2 (1.19 g, 5.27 mmol) in MeOH (13 mL) was refluxed overnight. After solvent removal in vacuo and digestion in ethylacetate, saturated aqueous NaHCO3 was added and the mixture was stirred overnight at room temperature. The mixture was filtered through Celite and organic layer was separated. The combined organic layer was washed with brine, dried (MgSO4) and concentrated. Purification by silica gel column chromatography (hexanes: EtOAc: MeOH = 6:3:1) gave 3-(6-bromo-imidazo[1,2-a]pyridin-2-yl)-phenylamine as a yellow solid (248 mg, 82% yield): Rf = 0.20 (hexanes:EtOAc:MeOH = 6:3:1); General procedure for the preparation of 5a-i. To a solution of the 3-(6-bromo-imidazo[1,2-a]pyridin-2-yl)-phenylamine (4) (1 equiv) and appropriate carboxylic acids (1.5-2 equiv) in DMF was added benzotriazol-1-yl-N-oxy-tris(pyrrolidino)-phosphonium hexafluorophosphate (PyBOP) (2 equiv) and N,N-diisopropylethylamine (DIPEA) (2 equiv) for 5a, 5h, and 5i, N, N, (2 equiv) and N,Ndiisopropylethylamine (DIPEA) (2 equiv) for 5b and 5e, Obenzotriazol-1-yl-N,N,N,N-tetramethyluronium hexafluorophosphate (HBTU) (3 equiv) and N,N-diisopropylethylamine (DIPEA) (3 equiv) for 5c, 1- [3-(dimethylamino) propyl]-3-ethylcarbodiimide hydrochloride (EDC) (1.5 equiv), 1-hydroxy-7-azabenzotriazole hydrate (HOAt) (1.5 equiv), and N,N-diisopropylethylamine (DIPEA) (1.5 equiv) for 5d, and 1- [3-(dimethyamino) propyl]-3-ethylcarbodiimide hydrochloride (EDC) (1.5 equiv), 1-hydroxylbenzotriazole hydrate (HOBt) (1.5 equiv), and N,N-diisopropylethylamine (DIPEA) (1.5 equiv) for 5f and 5g, respectively. The reaction mixture was stirred at room temperature overnight, and then partitioned between ethyl acetate and brine. The organic phase was dried (MgSO4) and concentrated. Purification by silica gel column chromatography or recrystallization gave the desired products.
3-(6-Bromo-imidazo[1,2-a]pyridin-2-yl)-phenylamine (4):
Thiophene - H-NMR (DMSOd6, 300 Hz) δ 10.9 (1H, s, NH), 8.93 (1H, m, aromatic), m, aromatic), 8.38 (1H, s, aromatic), m, aromatic), 8.14 (1H, d, J = 7.8 Hz, aromatic), m, aromatic), m, aromatic) (4) (62.7 mg, 0.22 mmol) and naphthalene-1-sulfonyl chloride (148 mg, 0.65 mmol) in CH2Cl2 (4 mL) was added triethylamine (0.03 mL, 0.22 mmol) portionwise at 0 o C. After stirring for 2 h, the solution was washed with aqueous 3% HCl, water and saturated aqueous NaHCO3. The organic layer was dried (MgSO4) and concentrated. Purification by preparative TLC (hexanes: EtOAc:MeOH = 6:3:1) gave naphthalene-1-sulfonic acid [3-(6-iodo-imidazo 
2-Biphenyl-4-yl-N-[3-(6-bromo-imidazo[1,2-a]pyridin-2-yl)-phenyl]-acetamide (5f):

min).
General procedure for the preparation of 6a-i. The napthalene-2-carboxylic acid [3-(6-bromo-imidazo[1,2-a] pyridin-2-yl)-phenyl]-amide (5c) (1 equiv) was added to a suspension of Pd(PPh3)4 (0.02 equiv) in degassed 1,2-dimethoxyethane (DME) at ambient temperature under nitrogen. The mixture was slowly heated to reflux with vigorous stirring overnight. The solution was cooled to ambient temperature and the appropriate boronic acid (1.2 equiv), sodium hydrogen carbonate (4 equiv) and H2O were added. The mixture was reheated reflux with vigorous stirring for 2 h, then cooled and extracted with ethyl acetate. The combined extracts were concentrated to afford a crude solid, which was purified by silica gel column chromatography or recrystallization.
Naphthalene - 1H, s, aromatic), 8.59 (1H, s, aromatic), 8.47 (1H, m, aromatic), 8.36 (1H, s, aromatic), 8.23 (1H, s, aromatic), 7.84-8.06 (8H, m, aromatic), 7.41-7.80 (9H, m, aromatic) 8.51 (1H, s, aromatic), 8.15 (2H, m, aromatic), 7.82-8.02 (4H, m, aromatic), 7.37-7.71 (9H, m, aromatic), 7.11 (1H, ps-t 1 H-NMR (CDCl 3 , 300 Hz) δ 8.70 (1H, s, NH), 8.41 (1H, s, aromatic), 8.22 (2H, d, J = 11.1 Hz, aromatic), m, aromatic), 7.63 (2H, d, J = 9.3 Hz, aromatic), m, aromatic), m, aromatic), m, aromatic), m, aromatic), 3.87 (3H, s, CH 3 1 H-NMR (DMSO-d6, 300 Hz) δ 11.34 (1H, s, NH), 9.06 (1H, s, aromatic), 8.66 (1H, s, aromatic), 8.54 (1H, s, aromatic), 8.38 (1H, s, aromatic), 8.26 (1H, s, aromatic), m, aromatic), 7.88 (2H, d, J = 7.2 Hz, aromatic), m, aromatic), 7.46 (1H, J = 7.8 Hz, aromatic) 1 H-NMR (DMSO-d6, 300 Hz) δ 10.6 (1H, s, NH), 9.09 (1H, s, aromatic), 8.66 (1H, s, aromatic), 8.55 (1H, s, aromatic), 8.43 (1H, s, aromatic), 8.01-8.13 (8H, m, aromatic), 7.86 (1H, m, aromatic), 7.64-7.76 (5H, m, aromatic) The resulting mixture was stirred overnight, and then acidified with 10% HCl to pH 2. The reaction mixture was filtered. The white solid was washed ethyl acetate and gave [4-(2-{3[(naphthalene-2-carbonyl) -amino]-phenyl}-imidazo[1,2-a] pyridin-6-yl)-phenoxy]-acetic acid as a white solid (28.5 mg, 83% yield): R f = 0.14 (CH 2 Cl 2 :MeOH = 6:1); 1 H-NMR (CD 3 OD, 300 Hz) δ 8.97 (1H, s, aromatic), m, aromatic), 8.18 (1H, dd, J = 9.3 Hz & 1.2 Hz, aromatic), m, aromatic), 7.78 (1H, m, aromatic), m, aromatic) Assay for ACAT and cholesterol ester formation in HepG2 cell. ACAT activity and cholesterol ester formation in HepG2 cells was assayed as described previously. 10 HepG2 cells were seeded in a 6 well plate at the density of 1×10 6 cells/mL/well and cultured in the medium containing 10% FBS for 2 days and then cultured overnight in the medium containing 5% LPDS(or 1% BSA). The medium was replaced and cells were incubated with 2.5 µL of sample or 0.1% DMSO, a vehicle of sample, and [l-14 C]oleic acid (0.5 µCi) for 6 hr in 6 well plate. Then, the medium was removed, and the cells were washed three times with PBS. The intracellular lipids of the cells were extracted by hexane/isopropanol (3:2) and the organic phase was evaporated under nitrogen. Total lipid was separated by silica gel TLC plate in petroleum ether/diethyl ether/acetic acid (90:10:1) and the amount of radioactivity was analyzed with a bioimagina analyzer (BAS-1500, FUJIFILM).
